Commitments and Contingencies (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024	May 15, 2025
Grant Repyable	$ 513,256
Future research and collaboration commitments	1,383,049
Long-term debt payable	6,788,723
Operating Lease Right of Use Obligations [Member]
Operating Lease Liabilities	91,358
Operating Lease Expense	93,107
Short Term Lease Costs	54,991
Gustave Roussy [Member]
Additional Cost Of Company	119,923
Due to related party	119,923
Collaborative Obligations Amount Due	$ 17,986
Convertible Notes Payable [Member]
Stock upon repayment or conversion description	ownership limitation equal to 4.99% of the Company’s outstanding shares of common stock; provided, that if Lind and its affiliates beneficially own in excess of 4.99% of the Company’s outstanding shares of common stock, then such limitation shall automatically increase to 9.99% so long as Lind and its affiliates own in excess of 4.99% of such common stock (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon Lind and its affiliates ceasing to own in excess of 4.99% of such common stock). Additionally, the issuance in the aggregate of any Note Shares and Warrant Shares in excess of 19.99% of the outstanding common stock shall be subject to stockholder approval in accordance with NYSE American Rule 713
Initial fair value description	(i) dividend yield of 0%; (ii) expected volatility of 99.99%; (iii) risk-free interest rate of 3.89%; (iv) discount rate of 42.95%; (v) simulated term of 1.92 years; (vi) estimated fair value of the common shares of $0.45 per share; and (vii) various probability assumptions. Subsequent changes in fair value are recognized in the statement of operations for each reporting period
Repayment Share Price description	The “Repayment Share Price” is defined in the Lind Note as ninety percent (90%) of the average of the five (5) lowest daily VWAPs during the twenty (20) trading days prior to the payment date
Convertible Promissory Note				$ 7,500,000
Warrant for purchase common stock	$ 13,020,834
Converted price				$ 0.72
Monthly payment	416,666
Monthly payments	1,000,000
Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member]
Additional Cost Of Company	245,319
Collaborative Obligations Amount Due	245,319
August Two Thousand Twenty Three [Member] | Guy's and St Thomas' NHS Foundation Trust [Member]
Additional Cost Of Company	144,786
Due to related party	144,786
Collaborative Obligations Amount Due	0
July Thirty One Thousand Twenty Three [Member] | Xenetic Biosciences Inc and CLS Therapeutics [Member]
Additional Cost Of Company	107,589
Due to related party	81,447
Collaborative Obligations Amount Due	81,447
October Two Thousand Twenty Four [Member] | National University of Taiwan Second [Member]
Additional Cost Of Company	402,250
Due to related party	281,575
Collaborative Obligations Amount Due	0
January 2024 [Member] | Xenetic Biosciences Inc and CLS Therapeutics [Member]
Additional Cost Of Company	0
Due to related party	0
Collaborative Obligations Amount Due	0
VolitionRx [Member] | In 2016 [Member] | Long-term Debt [Member]
Long-term debt payable	$ 162,483
Fixed Interest Rate On Lease	7.82%
Lease Payable	$ 294,603
Managing Director's Agreement [Member]
Due to related party	230
Royalty Payment	$ 129,477
Royality	6.00%
Clinical Study Research Agreement [Member] | University of Taiwan [Member] | In 2018 [Member]
Additional Cost Of Company	$ 510,000
Collaborative Obligations Amount Due	$ 2,550,000
Lease Agreement Expire Period	3 years
Restricted Stock Units [Member]
Recognized total compensation expense	$ 1,487,472		$ 527,940
RSU Vested in 2023	516,039
RSU Vested in 2024	443,493
Unrecognized compensation expense	37,264
Recognized total compensation expense	1,159,847	$ 614,028
Restricted Stock Units [Member] | One
Recognized total compensation expense	260,586
RSU Vested in 2023	348,453
RSU Vested in 2024	443,117
Unrecognized compensation expense	1,210,956
RSU Vested in 2027	419,386
Restricted Stock Units [Member] | Two
RSU Vested in 2023	25,019
Unrecognized compensation expense	109,420
RSU Vested in 2027	84,401
Recognized total compensation expense	$ 564,977